{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:45:22Z","timestamp":1776206722743,"version":"3.50.1"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2022QH322"],"award-info":[{"award-number":["ZR2022QH322"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2506700"],"award-info":[{"award-number":["2023YFC2506700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472366"],"award-info":[{"award-number":["82472366"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105036","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:49:45Z","timestamp":1763693385000},"page":"105036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting drug-tolerant persister cells to overcome resistance in HER2-positive gastric cancer"],"prefix":"10.1016","volume":"217","author":[{"given":"Qian","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linchuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyi","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanxin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiankang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4804-6140","authenticated-orcid":false,"given":"Guangyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/COC.0000000000000825","volume":"44","author":"Abali","year":"2021","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric Cancer, Version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","article-title":"Current developments in gastric cancer: from molecular profiling to treatment strategy","volume":"20","author":"Alsina","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105036_bib4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s43018-022-00402-0","article-title":"Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy","volume":"3","author":"\u00c1lvarez-Varela","year":"2022","journal-title":"Nat. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/onc.2013.540","article-title":"HER2\/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors","volume":"34","author":"Andrechek","year":"2015","journal-title":"Oncogene"},{"issue":"7517","key":"10.1016\/j.critrevonc.2025.105036_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Anon","year":"2014","journal-title":"Nature"},{"issue":"7636","key":"10.1016\/j.critrevonc.2025.105036_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma","volume":"541","author":"Anon","year":"2017","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.critrevonc.2025.105036_bib8","doi-asserted-by":"crossref","first-page":"11536","DOI":"10.1021\/jacs.2c03973","article-title":"Iron-sensitive prodrugs that trigger active ferroptosis in drug-tolerant pancreatic cancer cells","volume":"144","author":"Antoszczak","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.105036_bib9","doi-asserted-by":"crossref","first-page":"11018","DOI":"10.1158\/0008-5472.CAN-05-0491","article-title":"Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase\/AKT signaling pathway in breast cancer cells","volume":"65","author":"Asanuma","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105036_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101838","article-title":"Nanostructures for site-specific delivery of oxaliplatin cancer therapy: versatile nanoplatforms in synergistic cancer therapy","volume":"39","author":"Bagheri","year":"2024","journal-title":"Transl. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105036_bib11","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10120-022-01298-6","article-title":"Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab","volume":"25","author":"Bang","year":"2022","journal-title":"Gastric Cancer"},{"issue":"9742","key":"10.1016\/j.critrevonc.2025.105036_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105036_bib13","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1053\/j.gastro.2011.08.050","article-title":"HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells","volume":"141","author":"Bao","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2025.105036_bib14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clnesp.2025.03.023","article-title":"Prognostic significance of the cachexia index (CXI) in patients with cancer: a systematic review and meta-analysis","volume":"68","author":"Bas","year":"2025","journal-title":"Clin. Nutr. ESPEN"},{"key":"10.1016\/j.critrevonc.2025.105036_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.08.003","article-title":"Minimal residual disease in cancer therapy--Small things make all the difference","volume":"21-22","author":"Blatter","year":"2015","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","article-title":"HER2-positive gastric cancer","volume":"17","author":"Boku","year":"2014","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib17","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc.2016.124","article-title":"The recurrent architecture of tumour initiation, progression and drug sensitivity","volume":"17","author":"Califano","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105036_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(20)30326-0","article-title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial","volume":"21","author":"Catenacci","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105036_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","article-title":"Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN \u03b3 secretion","volume":"430","author":"Chaganty","year":"2018","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105036_bib21","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-20-1265","article-title":"Ontogeny and vulnerabilities of drug-tolerant persisters in HER2+ breast cancer","volume":"12","author":"Chang","year":"2022","journal-title":"Cancer Discov."},{"issue":"6924","key":"10.1016\/j.critrevonc.2025.105036_bib22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib24","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112491119","article-title":"Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer","volume":"119","author":"Cordero","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4730","key":"10.1016\/j.critrevonc.2025.105036_bib25","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.2999974","article-title":"Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene","volume":"230","author":"Coussens","year":"1985","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105036_bib26","first-page":"4892","article-title":"Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2","volume":"61","author":"Cuello","year":"2001","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canlet.2014.07.021","article-title":"Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH","volume":"353","author":"Das","year":"2014","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051118","article-title":"Fighting drug resistance through the targeting of drug-tolerant persister cells","volume":"13","author":"De Conti","year":"2021","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105036_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cells12202481","article-title":"SMYD3 modulates the HGF\/MET signaling pathway in gastric cancer","volume":"12","author":"De Marco","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib30","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10120-016-0627-z","article-title":"PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma","volume":"20","author":"Deguchi","year":"2017","journal-title":"Gastric Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105036_bib31","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5994","key":"10.1016\/j.critrevonc.2025.105036_bib33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/312545a0","article-title":"Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene","volume":"312","author":"Drebin","year":"1984","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21070965","article-title":"Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer","volume":"21","author":"Du","year":"2016","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105036_bib35","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/1535-7163.MCT-08-0860","article-title":"Epigenetics in cancer: targeting chromatin modifications","volume":"8","author":"Ellis","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105036_bib36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro.2017.42","article-title":"Persistent bacterial infections and persister cells","volume":"15","author":"Fisher","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrgastro.2011.81","article-title":"Anti-HER agents in gastric cancer: from bench to bedside","volume":"8","author":"Fornaro","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105036_bib38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105036_bib39","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1535-7163.MCT-23-0025","article-title":"Targeting upregulated cIAP2 in SOX10-deficient drug tolerant melanoma","volume":"22","author":"Glasheen","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"35","key":"10.1016\/j.critrevonc.2025.105036_bib40","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2013.48.9070","article-title":"Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab","volume":"31","author":"Gomez-Martin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105036_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12885-016-2092-9","article-title":"Optimal regimen of trastuzumab in combination with oxaliplatin\/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial","volume":"16","author":"Gong","year":"2016","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2017.07.002","article-title":"Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure","volume":"32","author":"Guler","year":"2017","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib43","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41419-021-03991-3","article-title":"miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer","volume":"12","author":"Guo","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib44","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat. Commun."},{"issue":"7679","key":"10.1016\/j.critrevonc.2025.105036_bib45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105036_bib46","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","article-title":"Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity","volume":"39","author":"Hanker","year":"2021","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib47","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC--A randomized phase III trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib50","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41571-023-00767-w","article-title":"Early stage gastric adenocarcinoma: clinical and molecular landscapes","volume":"20","author":"Hirata","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105036_bib51","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/cac2.12459","article-title":"Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer","volume":"43","author":"Hu","year":"2023","journal-title":"Cancer Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105036_bib52","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3389\/fonc.2019.01453","article-title":"Durable clinical response to pyrotinib after resistance to prior anti-HER2 therapy for HER2-positive advanced gastric cancer: a case report","author":"Huang","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib53","first-page":"294","article-title":"Correlation between HGF\/c-Met and Notch1 signaling pathways in human gastric cancer cells","volume":"40","author":"Huang","year":"2018","journal-title":"Oncol. Rep."},{"issue":"28","key":"10.1016\/j.critrevonc.2025.105036_bib54","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1200\/JCO.20.01210","article-title":"Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial","volume":"38","author":"Hyung","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib55","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"issue":"10418","key":"10.1016\/j.critrevonc.2025.105036_bib56","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105036_bib57","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","article-title":"First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial","volume":"21","author":"Janjigian","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib58","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10120-021-01176-7","article-title":"WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers","volume":"24","author":"Jin","year":"2021","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib59","first-page":"264","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105036_bib60","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.12998\/wjcc.v7.i15.1964","article-title":"HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer","volume":"7","author":"Kaito","year":"2019","journal-title":"World J. Clin. Cases"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105036_bib61","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1016\/j.cell.2022.07.025","article-title":"Sublethal cytochrome c release generates drug-tolerant persister cells","volume":"185","author":"Kalkavan","year":"2022","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib62","first-page":"3807","article-title":"MicroRNA signature for HER2-positive breast and gastric cancer","volume":"34","author":"Kang","year":"2014","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib63","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/cas.14316","article-title":"ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer","volume":"111","author":"Kawakami","year":"2020","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib64","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/oncolo\/oyab062","article-title":"Phase II study of continued trastuzumab plus irinotecan in patients with HER2-positive gastric cancer previously treated with trastuzumab (HGCSG 1201)","volume":"27","author":"Kawamoto","year":"2022","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105036_bib65","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1172\/JCI75200","article-title":"Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma","volume":"124","author":"Kim","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105036_bib66","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1593\/neo.13402","article-title":"TBK1 regulates prostate cancer dormancy through mTOR inhibition","volume":"15","author":"Kim","year":"2013","journal-title":"Neoplasia"},{"issue":"69","key":"10.1016\/j.critrevonc.2025.105036_bib67","doi-asserted-by":"crossref","first-page":"113494","DOI":"10.18632\/oncotarget.23054","article-title":"PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib68","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10120-017-0766-x","article-title":"Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)","volume":"21","author":"Kimura","year":"2018","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105036_bib69","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10120-014-0430-7","article-title":"Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer","volume":"18","author":"Kurokawa","year":"2015","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib70","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s10120-020-01112-1","article-title":"Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3)","volume":"24","author":"Kurokawa","year":"2021","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib71","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bjc.2014.18","article-title":"Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)","volume":"110","author":"Kurokawa","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib72","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41467-020-20717-9","article-title":"Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells","volume":"12","author":"Larrue","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib73","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/gutjnl-2024-332901","article-title":"Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk between CCL2+ fibroblasts and STAT3-activated macrophages","volume":"74","author":"Lee","year":"2025","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib74","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1038\/s41467-022-33267-z","article-title":"A single arm phase Ib\/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105036_bib75","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1309\/AJCPIRL4GUVGK3YX","article-title":"HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer","volume":"142","author":"Lee","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib76","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12957-017-1132-5","article-title":"The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","volume":"15","author":"Lei","year":"2017","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105036_bib77","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.taap.2018.09.044","article-title":"Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells","volume":"360","author":"Li","year":"2018","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105036_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216702","article-title":"Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer","volume":"587","author":"Liang","year":"2024","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib79","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41419-019-1362-2","article-title":"ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance","volume":"10","author":"Lin","year":"2019","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105036_bib80","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.105036_bib81","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","article-title":"Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)","volume":"93","author":"Lu","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105036_bib82","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrc.2017.125","article-title":"Targeting minimal residual disease: a path to cure?","volume":"18","author":"Luskin","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105036_bib83","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.19.03077","article-title":"Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study)","volume":"38","author":"Makiyama","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-pantumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105036_bib85","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"45","key":"10.1016\/j.critrevonc.2025.105036_bib86","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib87","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10120-018-0861-7","article-title":"Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer","volume":"22","author":"Mondaca","year":"2019","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib88","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13058-017-0868-8","article-title":"Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis","volume":"19","author":"Morrison Joly","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib89","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","article-title":"Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib90","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/annonc\/12.suppl_1.S9","article-title":"The role of overexpressed HER2 in transformation","volume":"12","author":"Neve","year":"2001","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105036_bib91","doi-asserted-by":"crossref","DOI":"10.1172\/JCI160152","article-title":"Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse","volume":"132","author":"Nie","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105036_bib92","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1158\/0008-5472.CAN-06-3155","article-title":"Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways","volume":"67","author":"Niu","year":"2007","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib93","doi-asserted-by":"crossref","first-page":"280","DOI":"10.15252\/embr.201439949","article-title":"Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure","volume":"16","author":"Pagliarini","year":"2015","journal-title":"EMBO Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105036_bib94","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40265-020-01272-5","article-title":"Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: current knowledge and future perspectives","volume":"80","author":"Palle","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105036_bib95","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/ijc.30408","article-title":"HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research","volume":"139","author":"Pietrantonio","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib96","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-17-2781","article-title":"Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study","volume":"24","author":"Pietrantonio","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105036_bib97","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/onc.2017.380","article-title":"CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2","volume":"37","author":"Qi","year":"2018","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105036_bib98","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105036_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083805","article-title":"Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: novel translational implications","volume":"22","author":"Rihawi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105036_bib100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2020.12.005","article-title":"Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial","volume":"145","author":"Rivera","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105036_bib101","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00280-019-03820-7","article-title":"Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial","volume":"83","author":"Rivera","year":"2019","journal-title":"Cancer Chemother. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105036_bib102","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10120-021-01182-9","article-title":"Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?","volume":"24","author":"Roviello","year":"2021","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib103","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"R\u00fcschoff","year":"2012","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib104","first-page":"85","article-title":"The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo","volume":"1","author":"Rusnak","year":"2001","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105036_bib105","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ejca.2014.12.015","article-title":"Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer","volume":"51","author":"Ryu","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105036_bib106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2018.09.024","article-title":"Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)","volume":"105","author":"Saeki","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib107","first-page":"1047","article-title":"Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas","volume":"77","author":"Sakai","year":"1986","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105036_bib108","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/1535-7163.MCT-19-0455","article-title":"HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer","volume":"18","author":"Sampera","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105036_bib109","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","article-title":"Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)","volume":"22","author":"Seo","year":"2019","journal-title":"Gastric Cancer"},{"issue":"7900","key":"10.1016\/j.critrevonc.2025.105036_bib111","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105036_bib112","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1200\/JCO.2016.71.6852","volume":"35","author":"Shah","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105036_bib113","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41388-018-0204-5","article-title":"The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition","volume":"37","author":"Shi","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib114","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/s41467-021-23053-8","article-title":"Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer","volume":"12","author":"Shi","year":"2021","journal-title":"Nat. Commun."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.105036_bib115","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib116","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ccell.2015.05.008","article-title":"Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia","volume":"28","author":"Shojaee","year":"2015","journal-title":"Cancer Cell"},{"issue":"7848","key":"10.1016\/j.critrevonc.2025.105036_bib117","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41586-020-03064-z","article-title":"Chromothripsis drives the evolution of gene amplification in cancer","volume":"591","author":"Shoshani","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.105036_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100851","article-title":"Long non-coding RNA mediated drug resistance in breast cancer","volume":"63","author":"Singh","year":"2022","journal-title":"Drug Resist Updat"},{"issue":"10251","key":"10.1016\/j.critrevonc.2025.105036_bib119","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib120","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamaoncol.2021.8196","article-title":"Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review","volume":"8","author":"Strickler","year":"2022","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib121","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3892\/etm.2017.4548","article-title":"Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer","volume":"14","author":"Sui","year":"2017","journal-title":"Exp. Ther. Med"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib122","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005063","article-title":"CD40\u00d7HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer","volume":"10","author":"Sun","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105036_bib123","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s43018-024-00819-9","article-title":"Targeting therapy-persistent residual disease","volume":"5","author":"Sun","year":"2024","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib124","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105036_bib126","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","article-title":"Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study","volume":"19","author":"Tabernero","year":"2018","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105036_bib127","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s10120-019-00973-5","article-title":"Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-na\u00efve, HER2-positive advanced gastric cancer","volume":"22","author":"Takahari","year":"2019","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105036_bib128","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.18632\/oncotarget.6753","article-title":"Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer","volume":"7","author":"Takahashi","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105036_bib129","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","article-title":"Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis","volume":"39","author":"Tanaka","year":"2021","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","article-title":"Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab","volume":"16","author":"Tanner","year":"2005","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105036_bib131","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrc3559","article-title":"Targeting the ERBB family in cancer: couples therapy","volume":"13","author":"Tebbutt","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105036_bib132","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20071697","article-title":"Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase","volume":"20","author":"Tokumaru","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib134","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10120-024-01467-9","volume":"27","author":"Tokunaga","year":"2024","journal-title":"Gastric Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105036_bib135","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib136","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib137","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105036_bib138","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","article-title":"Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer","volume":"53","author":"Wakatsuki","year":"2018","journal-title":"J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105036_bib139","doi-asserted-by":"crossref","first-page":"934","DOI":"10.20892\/j.issn.2095-3941.2023.0480","article-title":"Treatment strategies for patients with HER2-positive gastric cancer","volume":"20","author":"Wang","year":"2024","journal-title":"Cancer Biol. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105036_bib140","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/0008-5472.CAN-21-1820","article-title":"Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105036_bib141","article-title":"Comprehensive pan-cancer analysis identified NSD2 as a potential prognostic and diagnostic biomarker","volume":"45","author":"Wang","year":"2025","journal-title":"Cancer Treat. Res Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib142","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gutjnl-2018-316522","article-title":"Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer","volume":"68","author":"Wang","year":"2019","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105036_bib143","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/mc.22821","article-title":"Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib","volume":"57","author":"Wang","year":"2018","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib144","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib145","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10120-018-0887-x","article-title":"Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer","volume":"22","author":"Yagi","year":"2019","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105036_bib146","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/EBC20200032","article-title":"Non-coding RNA in cancer","volume":"65","author":"Yan","year":"2021","journal-title":"Essays Biochem."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib147","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105036_bib148","first-page":"1034","article-title":"Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer","volume":"51","author":"Yonemura","year":"1991","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105036_bib149","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1111\/bph.13961","article-title":"Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo","volume":"174","author":"Yu","year":"2017","journal-title":"Br. J. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00280-019-03991-3","article-title":"Multicenter phase II study of SOX plus trastuzumab for patients with HER2(+) metastatic or recurrent gastric cancer: KSCC\/HGCSG\/CCOG\/PerSeUS 1501B","volume":"85","author":"Yuki","year":"2020","journal-title":"Cancer Chemother. Pharm."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105036_bib151","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41575-022-00591-0","article-title":"The immune microenvironment in gastric adenocarcinoma","volume":"19","author":"Zavros","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib152","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","article-title":"Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: a phase II study","volume":"161","author":"Zhang","year":"2021","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105036_bib153","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114903","article-title":"Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy","volume":"14","author":"Zhang","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105036_bib154","article-title":"Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma","volume":"3","author":"Zhang","year":"2022","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib155","doi-asserted-by":"crossref","first-page":"20858","DOI":"10.1038\/s41598-023-47961-5","article-title":"Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p\/SOX2 axis in gastric cancer","volume":"13","author":"Zhao","year":"2023","journal-title":"Sci. Rep."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.105036_bib156","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study","volume":"37","author":"Zhong","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3-4","key":"10.1016\/j.critrevonc.2025.105036_bib157","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41417-017-0005-y","article-title":"miR-200c inhibits TGF-\u03b2-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer","volume":"25","author":"Zhou","year":"2018","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105036_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188549","article-title":"HER2-targeted therapies in gastric cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim Biophys. Acta Rev. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282500424X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282500424X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:13:44Z","timestamp":1773850424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282500424X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":158,"alternative-id":["S104084282500424X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105036","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting drug-tolerant persister cells to overcome resistance in HER2-positive gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105036"}}